Michael Wiederhorn
Stock Analyst at Oppenheimer
(2.60)
# 2,055
Out of 5,180 analysts
145
Total ratings
50%
Success rate
-0.59%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GRDN Guardian Pharmacy Services | Maintains: Outperform | $35 → $38 | $37.66 | +0.90% | 2 | Mar 12, 2026 | |
| PACS PACS Group | Maintains: Outperform | $40 → $42 | $32.12 | +30.76% | 4 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Outperform | $12 → $7 | $5.45 | +28.44% | 12 | Mar 3, 2026 | |
| EVH Evolent Health | Maintains: Outperform | $12 → $6 | $2.28 | +163.16% | 2 | Mar 2, 2026 | |
| CHE Chemed | Maintains: Outperform | $580 → $500 | $377.74 | +32.37% | 14 | Feb 27, 2026 | |
| UNH UnitedHealth Group | Maintains: Outperform | $415 → $385 | $270.59 | +42.28% | 18 | Jan 28, 2026 | |
| HCA HCA Healthcare | Maintains: Outperform | $500 → $540 | $473.24 | +14.11% | 13 | Jan 28, 2026 | |
| EHAB Enhabit | Upgrades: Outperform | $14 | $14.09 | -0.64% | 3 | Jan 22, 2026 | |
| CNC Centene | Maintains: Outperform | $51 → $43 | $32.74 | +31.34% | 19 | Jul 28, 2025 | |
| HUM Humana | Maintains: Outperform | $300 → $310 | $173.39 | +78.79% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $375 | $266.75 | +40.58% | 11 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $37 | $30.48 | +21.39% | 6 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $168 | $201.50 | -16.63% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $140 → $145 | $93.65 | +54.83% | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4.5 → $5 | $2.94 | +70.07% | 10 | Jul 25, 2024 |
Guardian Pharmacy Services
Mar 12, 2026
Maintains: Outperform
Price Target: $35 → $38
Current: $37.66
Upside: +0.90%
PACS Group
Mar 4, 2026
Maintains: Outperform
Price Target: $40 → $42
Current: $32.12
Upside: +30.76%
Teladoc Health
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $7
Current: $5.45
Upside: +28.44%
Evolent Health
Mar 2, 2026
Maintains: Outperform
Price Target: $12 → $6
Current: $2.28
Upside: +163.16%
Chemed
Feb 27, 2026
Maintains: Outperform
Price Target: $580 → $500
Current: $377.74
Upside: +32.37%
UnitedHealth Group
Jan 28, 2026
Maintains: Outperform
Price Target: $415 → $385
Current: $270.59
Upside: +42.28%
HCA Healthcare
Jan 28, 2026
Maintains: Outperform
Price Target: $500 → $540
Current: $473.24
Upside: +14.11%
Enhabit
Jan 22, 2026
Upgrades: Outperform
Price Target: $14
Current: $14.09
Upside: -0.64%
Centene
Jul 28, 2025
Maintains: Outperform
Price Target: $51 → $43
Current: $32.74
Upside: +31.34%
Humana
May 1, 2025
Maintains: Outperform
Price Target: $300 → $310
Current: $173.39
Upside: +78.79%
Jan 31, 2025
Maintains: Outperform
Price Target: $400 → $375
Current: $266.75
Upside: +40.58%
Nov 8, 2024
Maintains: Outperform
Price Target: $34 → $37
Current: $30.48
Upside: +21.39%
Oct 25, 2024
Maintains: Outperform
Price Target: $165 → $168
Current: $201.50
Upside: -16.63%
Sep 23, 2024
Maintains: Outperform
Price Target: $140 → $145
Current: $93.65
Upside: +54.83%
Jul 25, 2024
Maintains: Outperform
Price Target: $4.5 → $5
Current: $2.94
Upside: +70.07%